# Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00735371** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 314 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** LDX 30 mg
- **DRUG:** LDX 50 mg
- **DRUG:** LDX 70 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00735371
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-08
- **Primary completion:** 2009-04-06
- **Final completion:** 2009-04-06
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735371, "Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00735371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*